JP2021527651A5 - - Google Patents
Info
- Publication number
- JP2021527651A5 JP2021527651A5 JP2020570030A JP2020570030A JP2021527651A5 JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5 JP 2020570030 A JP2020570030 A JP 2020570030A JP 2020570030 A JP2020570030 A JP 2020570030A JP 2021527651 A5 JP2021527651 A5 JP 2021527651A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sarna
- additional activator
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024087660A JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685627P | 2018-06-15 | 2018-06-15 | |
| US62/685,627 | 2018-06-15 | ||
| US201862731532P | 2018-09-14 | 2018-09-14 | |
| US62/731,532 | 2018-09-14 | ||
| US201962821533P | 2019-03-21 | 2019-03-21 | |
| US62/821,533 | 2019-03-21 | ||
| PCT/GB2019/051654 WO2019239144A1 (en) | 2018-06-15 | 2019-06-14 | Combination therapies comprising c/ebp alpha sarna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Division JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527651A JP2021527651A (ja) | 2021-10-14 |
| JP2021527651A5 true JP2021527651A5 (https=) | 2022-06-20 |
Family
ID=67070873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570030A Pending JP2021527651A (ja) | 2018-06-15 | 2019-06-14 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087660A Withdrawn JP2024103632A (ja) | 2018-06-15 | 2024-05-30 | Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210254069A1 (https=) |
| EP (1) | EP3807410A1 (https=) |
| JP (2) | JP2021527651A (https=) |
| CN (1) | CN112543809A (https=) |
| AU (1) | AU2019285344A1 (https=) |
| CA (1) | CA3102334A1 (https=) |
| WO (1) | WO2019239144A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020330133A1 (en) * | 2019-08-14 | 2022-03-17 | Lonza Sales Ag | Extracellular vesicle-ASO constructs targeting CEBP/beta |
| TW202535468A (zh) * | 2020-05-12 | 2025-09-16 | 瑞典商阿斯特捷利康公司 | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 |
| CN111876390B (zh) * | 2020-08-12 | 2021-04-09 | 湖南南华爱世普林生物技术有限公司 | 负载化合物的转基因干细胞外泌体在制备药物或美白化妆品中的用途 |
| EP4329777A1 (en) * | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
| CN114306367B (zh) * | 2021-08-27 | 2023-03-28 | 赵小洋 | 一种含有C/EBPα-saRNA的组合物 |
| WO2024175887A1 (en) * | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| AU5613999A (en) | 1998-09-18 | 2000-04-10 | University Of British Columbia, The | Pharmaceutical compositions of vanadium biguanide complexes and their use |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EP1854880A1 (en) | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| EP1871426B1 (en) | 2005-04-15 | 2017-06-07 | The Regents of The University of California | Small activating rna molecules and their use |
| WO2007086990A2 (en) | 2005-11-17 | 2007-08-02 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal dna |
| US8748815B2 (en) | 2006-08-31 | 2014-06-10 | Hermes Microvision, Inc. | Method and system for detecting or reviewing open contacts on a semiconductor device |
| EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| JP2010510222A (ja) * | 2006-11-17 | 2010-04-02 | シェーリング コーポレイション | 増殖性障害に対する併用療法 |
| WO2010124231A2 (en) | 2009-04-24 | 2010-10-28 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
| CN101941001B (zh) | 2009-07-03 | 2014-04-02 | 3M创新有限公司 | 亲水涂层、制品、涂料组合物和方法 |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2012046085A2 (en) | 2010-10-08 | 2012-04-12 | Mina Therapeutics Limited | Methods of inducing insulin production |
| KR102195514B1 (ko) | 2011-06-21 | 2020-12-29 | 미나 테라퓨틱스 리미티드 | 알부민 생산 및 세포 증식 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| SI3071696T1 (sl) * | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| KR102599712B1 (ko) * | 2015-04-22 | 2023-11-09 | 미나 테라퓨틱스 리미티드 | C/EBP 알파 saRNA 조성물 및 사용 방법 |
| ES2972458T3 (es) * | 2016-02-10 | 2024-06-12 | Bioinvent Int Ab | Combinación de anticuerpo humano anti-FGFR4 y sorafenib |
| WO2018049233A1 (en) * | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
-
2019
- 2019-06-14 US US17/252,593 patent/US20210254069A1/en not_active Abandoned
- 2019-06-14 AU AU2019285344A patent/AU2019285344A1/en not_active Abandoned
- 2019-06-14 WO PCT/GB2019/051654 patent/WO2019239144A1/en not_active Ceased
- 2019-06-14 JP JP2020570030A patent/JP2021527651A/ja active Pending
- 2019-06-14 CN CN201980040237.3A patent/CN112543809A/zh active Pending
- 2019-06-14 CA CA3102334A patent/CA3102334A1/en active Pending
- 2019-06-14 EP EP19733859.3A patent/EP3807410A1/en active Pending
-
2024
- 2024-05-30 JP JP2024087660A patent/JP2024103632A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527651A5 (https=) | ||
| Kružliak et al. | Vascular endothelial growth factor inhibitor–induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors | |
| JP2018536689A5 (https=) | ||
| SG10201903290YA (en) | Modified double-stranded rna agents | |
| JP2017537070A5 (https=) | ||
| KR20170139055A (ko) | 백금계 항암제에 의해 유도된 세포 내 증가된 p53 수준을 유지시키는 방법 및 이의 활용 | |
| Philippi et al. | Telomerase as an emerging target to fight cancer—Opportunities and challenges for nanomedicine | |
| JP2012505660A5 (https=) | ||
| RU2017120536A (ru) | Способы и композиции для модулирования экспрессии аполипопротеина (а) | |
| JP2019506862A5 (https=) | ||
| JP2019512543A5 (https=) | ||
| Qian et al. | Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth | |
| JP2017536408A5 (https=) | ||
| JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
| Zhou et al. | Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p. | |
| Kelly et al. | Chemotherapy in metastatic colorectal cancer | |
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| Du et al. | Kaempferide enhances type I interferon signaling as a novel broad-spectrum antiviral agent | |
| Jian et al. | A nti‐lymphangiogenesis effects of a specific anti‐interleukin 7 receptor antibody in lung cancer model in vivo | |
| JP2016533190A5 (https=) | ||
| JP2021500026A5 (https=) | ||
| Tong et al. | Recombinant nematode anticoagulant protein c2 inhibits cell invasion by decreasing uPA expression in NSCLC cells | |
| KR102276343B1 (ko) | 혈관차단제로 유용한 벤조페논 티아졸 유도체 및 토포이소머라제 억제제를 포함하는 암의 예방 또는 치료용 약학적 조합물 | |
| Damjanovic et al. | Evidence‐based update of chemotherapy options for metastatic colorectal cancer | |
| Garcia et al. | Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma |